SG Americas Securities LLC Invests $108,000 in CVRx, Inc. (NASDAQ:CVRX)

SG Americas Securities LLC bought a new position in CVRx, Inc. (NASDAQ:CVRX) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 12,253 shares of the company’s stock, valued at approximately $108,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. Johnson & Johnson lifted its position in shares of CVRx by 17.4% in the 1st quarter. Johnson & Johnson now owns 4,103,430 shares of the company’s stock valued at $74,723,000 after acquiring an additional 607,855 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of CVRx by 5.6% in the first quarter. Vanguard Group Inc. now owns 594,312 shares of the company’s stock valued at $10,822,000 after purchasing an additional 31,720 shares in the last quarter. Silvercrest Asset Management Group LLC boosted its position in shares of CVRx by 70.7% in the first quarter. Silvercrest Asset Management Group LLC now owns 253,968 shares of the company’s stock worth $4,625,000 after buying an additional 105,198 shares during the period. FourWorld Capital Management LLC purchased a new position in shares of CVRx during the first quarter valued at $374,000. Finally, Bank of New York Mellon Corp raised its position in CVRx by 30.7% during the second quarter. Bank of New York Mellon Corp now owns 37,191 shares of the company’s stock valued at $446,000 after buying an additional 8,741 shares during the period. 75.27% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

CVRX has been the subject of a number of research reports. Piper Sandler decreased their price objective on CVRx from $15.00 to $13.00 and set an “overweight” rating for the company in a research report on Tuesday, July 30th. Canaccord Genuity Group boosted their price objective on shares of CVRx from $14.00 to $15.00 and gave the company a “buy” rating in a research report on Tuesday, July 30th. Craig Hallum cut their target price on shares of CVRx from $23.00 to $15.00 and set a “buy” rating for the company in a research report on Thursday, July 11th. Cantor Fitzgerald reissued an “overweight” rating and set a $14.00 target price on shares of CVRx in a research note on Wednesday, October 23rd. Finally, Lake Street Capital reaffirmed a “buy” rating and issued a $12.00 price target on shares of CVRx in a research note on Monday, August 26th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $13.67.

CVRx Stock Down 0.4 %

CVRx stock opened at $10.07 on Monday. The company has a market capitalization of $217.47 million, a P/E ratio of -4.08 and a beta of 1.26. CVRx, Inc. has a 1-year low of $6.40 and a 1-year high of $33.13. The firm’s fifty day simple moving average is $8.77 and its 200-day simple moving average is $9.65. The company has a current ratio of 10.08, a quick ratio of 8.85 and a debt-to-equity ratio of 0.53.

CVRx (NASDAQ:CVRX) last issued its quarterly earnings data on Monday, July 29th. The company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.14). CVRx had a negative net margin of 122.52% and a negative return on equity of 77.62%. The company had revenue of $11.81 million for the quarter, compared to analyst estimates of $11.84 million. During the same period in the prior year, the company posted ($0.56) EPS. Sell-side analysts forecast that CVRx, Inc. will post -2.56 earnings per share for the current fiscal year.

Insider Buying and Selling at CVRx

In other news, CEO Kevin Hykes bought 30,000 shares of the business’s stock in a transaction on Monday, August 5th. The stock was purchased at an average price of $8.36 per share, with a total value of $250,800.00. Following the transaction, the chief executive officer now directly owns 30,000 shares in the company, valued at approximately $250,800. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders have purchased a total of 38,500 shares of company stock worth $322,545 over the last 90 days. Insiders own 18.90% of the company’s stock.

About CVRx

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.